COVID-19 patients who could most benefit from Paxlovid still aren't getting it

Sticker shock has stunned thousands of Americans sick with COVID-19 since late December, as Pfizer shifted to commercial sales of Paxlovid. Before then, the federal government covered the cost of the drug.